Collegium Pharmaceutical
Abuse-deterrent Pharmaceutical Products for Chronic Pain.
Launch date
Employees
Market cap
€1.1b
Enterprise valuation
€1.3b (Public information from Sep 2024)
Share price
$38.78 COLL
Cumberland Maryland (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 310m | 277m | 464m | 567m | 618m | 703m | 714m |
| % growth | 4 % | (11 %) | 68 % | 22 % | 9 % | 14 % | 2 % |
| EBITDA | 56.5m | 22.2m | 34.4m | 332m | 399m | 433m | 428m |
| % EBITDA margin | 18 % | 8 % | 7 % | 59 % | 65 % | 62 % | 60 % |
| Profit | 26.8m | 71.5m | (25.0m) | 48.2m | 106m | 141m | 168m |
| % profit margin | 9 % | 26 % | (5 %) | 8 % | 17 % | 20 % | 24 % |
| EV / revenue | 2.5x | 2.4x | 1.7x | 1.8x | 3.0x | 2.1x | 1.7x |
| EV / EBITDA | 13.7x | 29.3x | 22.7x | 3.0x | 4.7x | 3.5x | 2.9x |
| R&D budget | 9.8m | 9.5m | 4.0m | - | - | - | - |
| R&D % of revenue | 3 % | 3 % | 1 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$3.0m | Series A | ||
$3.5m | Series B | ||
$5.5m | Series C | ||
$20.0m | Series D | ||
| N/A | $1.0m | Debt | |
$22.5m | Late VC | ||
| N/A | $4.0m | Early VC | |
N/A | Grant | ||
$50.0m | Late VC | ||
| N/A | N/A | IPO | |
* | N/A | $203m | Post IPO Debt |
* | $646m | Post IPO Debt | |
| Total Funding | €98.6m | ||
Related Content
Recent News about Collegium Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Collegium Pharmaceutical
Edit
ACQUISITION by Collegium Pharmaceutical Feb 2022
ACQUISITION by Collegium Pharmaceutical Jul 2024